title: Truncated isoforms inhibit [3H]prazosin binding and cellular trafficking of native human alpha1A-adrenoceptors.
abstract: We have identified from human liver eight alpha(1A)-adrenoceptor (alpha(1A)-AR) splice variants that were also expressed in human heart, prostate and hippocampus. Three of these alpha(1A)-AR isoforms (alpha(1A-1)-AR, alpha(1A-2a)-AR and alpha(1A-3a)-AR) gave rise to receptors with seven transmembrane domains (7TMalpha(1A)-AR). The other five (alpha(1A-2b)-AR, alpha(1A-2c)-AR, alpha(1A-3c)-AR, alpha(1A-5)-AR and alpha(1A-6)-AR) led to truncated receptors lacking transmembrane domain VII (6TMalpha(1A)-AR). The 7TMalpha(1A)-AR isoforms transiently expressed in COS-7 cells bound [(3)H]prazosin with high affinity (K(d) 0.2 nM) and mediated a noradrenaline (norepinephrine)-induced increase in cytoplasmic free Ca(2+) concentration, whereas the 6TMalpha(1A)-AR isoforms were incapable of ligand binding and signal transduction. Immunocytochemical studies with N-terminal epitope-tagged alpha(1A)-AR isoforms showed that the 7TMalpha(1A)-AR isoforms were present both at the cell surface and in intracellular compartments, whereas the 6TMalpha(1A)-AR isoforms were exclusively localized within the cell. Interestingly, in co-transfected cells, each truncated alpha(1A)-AR isoform inhibited [(3)H]prazosin binding and cell-surface trafficking of the co-expressed 'original' 7TMalpha(1A-1)-AR. However, there was no modification of either the [(3)H]prazosin-binding affinity or the pharmacological properties of alpha(1A-1)-AR. Immunoblotting experiments revealed that co-expression of the alpha(1A-1)-AR with 6TMalpha(1A)-AR isoforms did not impair alpha(1A-1)-AR expression. Therefore the expression in human tissues of many truncated isoforms constitutes a new regulation pathway of biological properties of alpha(1A)-AR.
authors.affiliation: Institut de Recherches Servier, Division de Pharmacologie Moléculaire et Cellulaire, 125 chemin de Ronde, 78 290 Croissy sur Seine, France. coge@servier.fr
authors.forename: F
authors.initials: F
authors.lastname: Cogé
authors.forename: S P
authors.initials: SP
authors.lastname: Guenin
authors.forename: A
authors.initials: A
authors.lastname: Renouard-Try
authors.forename: H
authors.initials: H
authors.lastname: Rique
authors.forename: C
authors.initials: C
authors.lastname: Ouvry
authors.forename: N
authors.initials: N
authors.lastname: Fabry
authors.forename: P
authors.initials: P
authors.lastname: Beauverger
authors.forename: J P
authors.initials: JP
authors.lastname: Nicolas
authors.forename: J P
authors.initials: JP
authors.lastname: Galizzi
authors.forename: J A
authors.initials: JA
authors.lastname: Boutin
authors.forename: E
authors.initials: E
authors.lastname: Canet
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001692:Biological Transport; D015153:Blotting, Western; D019556:COS Cells; D003001:Cloning, Molecular; D018076:DNA, Complementary; D006801:Humans; D008099:Liver / Q000378:metabolism; D008969:Molecular Sequence Data; D011224:Prazosin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011485:Protein Binding; D020033:Protein Isoforms / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D011869:Radioligand Assay; D018340:Receptors, Adrenergic, alpha-1 / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D017386:Sequence Homology, Amino Acid; D013347:Subcellular Fractions / Q000378:metabolism; D014316:Tritium
chemical_list: C547713:ADRA1A protein, human; D018076:DNA, Complementary; D020033:Protein Isoforms; D018340:Receptors, Adrenergic, alpha-1; D014316:Tritium; D011224:Prazosin